Variables influencing the risk of dissemination and outcome of Cryptococcus neoformans infection were assessed in 111 organ transplant recipients with cryptococcosis in a prospective, multicenter, international study. Sixtyone percent (68/111) of the patients had disseminated infection. The risk of disseminated cryptococcosis was significantly higher for liver transplant recipients (adjusted hazard ratio [HR], 6.65;
Variables influencing the risk of dissemination and outcome of Cryptococcus neoformans infection were assessed in 111 organ transplant recipients with cryptococcosis in a prospective, multicenter, international study. Sixtyone percent (68/111) of the patients had disseminated infection. The risk of disseminated cryptococcosis was significantly higher for liver transplant recipients (adjusted hazard ratio [HR], 6.65;
). The overall P p .048 mortality rate at 90 days was 14% (16/111). The mortality rate was higher in patients with abnormal mental status ( ), renal failure at baseline ( ), fungemia ( ), and disseminated infection P p .023 P p .028 P p .006 ( ) and was lower in those receiving a calcineurin-inhibitor agent ( ). In a multivariable analysis, P p .035 P p .003 the receipt of a calcineurin-inhibitor agent was independently associated with a lower mortality (adjusted HR, 0.21; ), and renal failure at baseline with a higher mortality rate (adjusted HR, 3.14; ). Thus, P p .008 P p .037 outcome in transplant recipients with cryptococcosis appears to be influenced by the type of immunosuppressive agent employed. Additionally, discerning the basis for transplant type-specific differences in disease severity has implications relevant for yielding further insights into the pathogenesis of C. neoformans infection in transplant recipients.
Invasive fungal infections occur in 15%-42% of organ transplant recipients [1, 2] . Refinements in surgical techniques and antifungal prophylaxis have led to a decrease in the overall incidence of fungal infections in the early posttransplant period, particularly for invasive candidiasis [3, 4] . The risk factors for cryptococcal in- that limiting the exposure is unlikely to curtail the risk of cryptococcosis. Mortality rates in transplant recipients with cryptococcosis typically range from 15% to 20% and approach 40% in those with central nervous system (CNS) infection [5, 6, 10] , suggesting a need to better understand the variables that affect outcome in these patients. Factors that impact outcome in other hosts have yielded insights that are relevant to prognosis in transplant recipients as well [11] [12] [13] [14] . However, organ transplant patients are unique in that the calcineurin-inhibitor-based immunosuppressive regimens employed in these patients have antifungal activity in vitro [15] [16] [17] and could potentially modify the extent of infection or its prognosis. Thus, assessment of the characteristics and outcome of Cryptococcus neoformans infection specifically in organ transplant recipients is important. In a multicenter study, we determined the extent to which the risk of dissemination and mortality in organ transplant recipients with cryptococcosis can be predicted by readily assessable clinical and laboratory variables.
PATIENTS AND METHODS

Patients.
The study population included 111 organ transplant recipients with C. neoformans infection at participating centers in the United States, Canada, Spain, France, and India. These patients represented 98.2% (111/113) of the cases of cryptococcosis in transplant recipients at our institutions during the study period; 2 patients diagnosed and followed at a site remote from the transplant center could not be enrolled. Patients included from France were transplant recipients who developed cryptococcosis during the study period and were enrolled in a nationwide, multicenter, prospective study of the French Cryptococcosis Study Group. The study was conducted between December 1999 and March 2006; the timing of initiation varied at different sites. Institutional review board approval was obtained as per local requirements.
Definitions. C. neoformans infection was defined as per the criteria proposed by the European Organization for Research and Treatment in Cancer and the Mycoses Study Group: positive cultures for C. neoformans in a clinical specimen, including blood cultures; histopathologic or cytopathologic examination of specimens of needle aspiration or biopsy showing encapsulated yeast cells; or positive cryptococcal antigen in the blood or cerebrospinal fluid in a patient with compatible clinical presentation [18] . Variables assessed included demographic characteristics, immunosuppressive regimen at the time of diagnosis, rejection episodes or antifungal agent use within 6 months before the onset of infection, cytomegalovirus infection, renal failure (defined as creatinine level у2 mg/dL) at the time of diagnosis, sites of infection, cerebrospinal fluid characteristics, antifungal therapy employed, and patient outcome. In all cases, the primary immunosuppressive agent at diagnosis was the patient's stable immunosuppressive regimen that had remained unchanged within the previous 6 months. Organ sites involved were classified as CNS; pulmonary; skin, soft-tissue, and osteoarticular; or other [5, 19] . Disseminated infection was defined as CNS infection or fungemia or involvement of у2 noncontiguous organ sites [5, 19] . As in previous studies on opportunistic mycoses, including cryptococcosis, the mortality rate was assessed at 90 days [11, 20] .
Statistical analysis. Intercooled Stata software (version 9.2; StataCorp) was used for all analyses. Logistic regression models were used to calculate odds ratios and confidence intervals (CIs) for factors associated with disseminated infection; no adjustments were made for multiple comparisons. A multivariable model was developed to assess for the effect of several factors as risks for disseminated infection. For this model, backward selection was used with factors removed at . Interaction P 1 .20 terms were generated and evaluated for the main effect factors in this model. Interaction terms were entered one at a time and dropped from the model if not statistically significant ( ). The Cox proportional hazards model was used to P ! 1.0 evaluate factors associated with mortality. Entry time was the date of diagnosis, and follow-up ended with death or 90 days after diagnosis. A multivariable model was generated using backward selection with factors removed at . Interaction P 1 .20 terms were generated and evaluated for the main effect factors in this model. Interaction terms were entered one at a time and dropped from the model if not statistically significant ( ). Schoenfeld residuals were used to test the propor-P ! 1.0 tional hazards assumption. Treatment with amphotericin B was forced into the final model to adjust for potential effect of therapy.
RESULTS
The clinical and demographic characteristics of the study patients are outlined in table 1. Cryptococcosis occurred a median of 21 months after transplantation; 68.5% of the infections developed 11 year after transplant.
Disseminated infection. Fifty-four percent (60/111) of patients had pulmonary infection, 52.2% (58/111) had CNS, and 8.1% (15/111) had skin, soft-tissue, or osteoarticular infections (table 2) . Sixty-one percent (68/111) of the patients had disseminated cryptococcosis, and, in 32.4% (36/111) of the patients, the infection was limited to the lungs. Patients receiving a calcineurin-inhibitor-based regimen (tacrolimus or cyclosporine A) were significantly less likely to have CNS infection (48% [46/96] ). Patients receiving a cal-P p .001 cineurin-inhibitor-based regimen, compared with those receiving a non-calcineurin-inhibitor-based regimen, were older (mean age, 52 vs. 41 years;
), more likely to have cryp-P p .01 tococcosis 11 year after transplant (100% vs. 63%; ), P p .003 and less likely to be kidney transplant recipients (46% vs. 87%;
). However, age, time to onset of infection, and type P p .004 of transplant were not significantly associated with mortality (table 4). Details of antifungal therapy have been discussed elsewhere [19] and are not the focus of this report. Briefly, 66.6% (74/111) of all patients and 90% (60/66) of those with disseminated infections were treated with amphotericin B for- ). P p .001
DISCUSSION
Several observations from the present study are relevant to cryptococcosis in transplant recipients. In all, 61% of the infections were disseminated, and the risk of dissemination was significantly higher for liver transplant recipients even when controlled for the immunosuppressive regimen. A number of possible reasons could account for this. Liver disease per se appears to be associated with more-severe presentation and poorer outcome in cryptococcosis. Patients with cirrhosis were more likely to develop septic shock, and cirrhosis of the liver was an independent predictor of mortality in cryptococcocemia [21] . Specific deficits in chemotaxis, complement deficiency, and monocyte suppressor cell activity in liver dysfunction were proposed to be the basis for these findings [21] . Although intact cell-mediated immunity is critical, antibody responses also contribute to the pathogenesis of cryptococcal disease [22] [23] [24] . Transplant recipients with cryptococcosis had higher titers of IgM and IgG to glucoronoxylomannan than those who did not develop this infection after transplantation [25] . That antibody worsens disease expression may seem intuitively paradoxical, but it is plausible because a prozone-like effect enhances severity and increases mortality in experimental cryptococcosis [26, 27] . Liver transplant recipients have a lower frequency of posttransplant hypogammaglobulinemia due to immunonusuppressive therapy than other transplant recipients [28] [29] [30] . Given that hepatic sinusoidal and Kupffer cells play a role in the clearance of immunoglobulins [31] , a decrease in cryptococcal-specific or nonspecific immunoglobulins may be substantially less or protracted in liver transplant recipients than in other transplant recipients, thus enhancing their susceptibility (loss of resistance) to cryptococcosis. Finally, hepatic iron overload in liver transplant recipients may also enhance fungal virulence [32] .
We note that a greater propensity of liver transplant recipients to develop disseminated infection has also been observed for aspergillosis. Historically, disseminated invasive aspergillosis has been documented in 50%-60% of liver transplant recipients, compared with 6%-35% of other organ transplant recipients [33] [34] [35] [36] . Notably, despite the requirement of a higher degree of immunosuppression, most Aspergillus infections in lung transplant recipients are limited to the lungs, with disseminated infections occurring in ∼6%-16% of the patients [36, 37] . This suggests that immune defects that facilitate the evasion of host defenses by these opportunistic mycoses are Figure 1 . Kaplan-Meier survival analysis showing that the probability of survival after the diagnosis of cryptococcosis was significantly higher in patients who received a calcineurin-inhibitor agent (tacrolimus or cyclosporine A) than in those who received azathioprine or mycophenolate mofetil without a calcineurin-inhibitor agent ( , log rank test). P p .001 greater in magnitude or that certain deficits occur uniquely in liver transplant recipients.
Tacrolimus (FK506) and cyclosporine exert their immunosuppressive effect by inhibiting calcineurin, a T cell signaling molecule [16, 38] . Although highly conserved from human to yeast, calcineurin is also identified in fungi and plays a vital role in cell biology in pathogenic fungi, including cellular morphogenesis and virulence in C. neoformans [39, 40] . Calcineurin-inhibitor agents have potent in vitro antifungal activity against C. neoformans that is mediated through inhibition of fungal homologs of calcineurin [16, 41] . The MIC of FK506 at 37ЊC for C. neoformans was !0.09 mg/mL, and that for cyclosporine A was 0.39-5 mg/mL [15] . Despite in vitro activity against C. neoformans, cyclosporine A was associated with progressive infection in an animal model of cryptococcal meningitis [42] . Cyclosporine A, however, penetrates the CNS less effectively than tacrolimus [5, 42] . Given that transplant recipients receiving calcineurin-inhibitor agents develop cryptococcosis, the immunosuppressive effect, compared with the antifungal effect, appears to predominate in the clinical setting. However, the use of these agents appeared to confer a protective effect on mortality that was particularly notable for tacrolimus. Whether this association is due to antifungal attributes of tacrolimus or other unmeasured variables pertaining to the host or infection in our patients remains to be determined. The association of renal failure with poor outcome in opportunistic mycoses, including cryptococcosis, has been reported elsewhere [5] .
Cryptococcosis has been reported after zoonotic exposure and in outbreak settings [43, 44] . However, a vast majority of the cases are considered to be due to reactivation of strains acquired long before clinical disease-likely during early childhood-and sequestered in alveolar macrophages [7, 9] . Patients receiving a calcineurin-inhibitor agent in the present study were less likely to have CNS involvement and more likely to have infection limited to the lungs. Thus, these agents might inhibit fungal calcineurin in strains emerging from the dormant phase and decrease dissemination from lungs and hilar lymph nodes to the CNS. However, the association of calcineurin-inhibitor agents with mortality was much stronger than the association of these agents with the risk of dissemination, suggesting that their protective effect on mortality may be mediated by other mechanisms as synergy with antifungal agents. The combination of FK506 and fluconazole is synergistic in vitro for C. neoformans and resulted in a ∼30-fold decrease in the MIC of FK506 and a 4-fold decrease in that of fluconazole for this yeast [45] . Whether outcomes in patients receiving immunophilinbinding immunosuppressive agents can be further improved by employing therapeutic interventions that synergistically target calcineurin or signaling pathways distinct from it remains to be determined.
There are limitations of the present study that deserve to be acknowledged. Because this was not a clinical trial, neither the immunosuppressive regimen nor antifungal therapy was randomized. There was also a significant difference in the time of onset of infection posttransplant, with more patients who received a non-calcineurin-inhibitor-based regimen having later onset of cryptococcosis. However, this finding would tend to bias the outcome, if at all, in favor of the non-calcineurin- inhibitor-agent group because cummulative immunosuppression is generally lower and outcomes in opportunistic infections are better in the late posttransplant period. Although we found no statistically significant association between the time to onset and the risk of disseminated infection or mortality, it is possible that timing or yet-unknown factors influenced the course of infection. Among the strengths of the present study is that it included a large cohort of patients in a prospective, multicenter design, which renders our findings generalizable to other transplant recipients with cryptococcosis. In summary, our data show that cryptococcosis remains a significant complication in organ transplant recipients. The outcome and to some extent the spectrum of infection appear to be influenced by the receipt of calcineurin-inhibitor-based immunosuppression. Calcineurin-inhibitor agents remain the mainstay of immunosuppression; however, long-term outcomes in transplant recipients receiving these drugs are suboptimal. Renal dysfunction, metabolic toxicity, and cardiovascular complications due to cumulative exposure to calcineurin-inhibitor agents [46, 47] have spawned a growing interest in the use of induction therapy, with the aim of achieving calcineurin-free/ sparing maintenance immunosuppression after transplantation [48, 49] . The impact of these evolving strategies on the spectrum of infectious complications, including cryptococcosis, remains to be determined. Finally, future studies to discern the precise basis for organ-specific differences in disease expression and severity of opportunistic mycoses have the potential to yield further insights into the pathogenesis of these infections in transplant recipients.
CRYPTOCOCCAL COLLABORATIVE TRANSPLANT STUDY GROUP
